Apalutamide Looking Good as Treatment for Non-Metastatic Castrate Resistant Prostate Cancer

Non-Metastatic Castrate Resistant Prostate Cancer (nmCRPC)  usually leads to metastatic prostate cancer and death. There are no approved treatments for nmCRPC. Apalutamide is a taken-by-mouth androgen receptor inhibitor with antitumor activity in CRPC. There's a much talked and written about clinical trial called, SPARTAN, that investigated how well Apalutamide works on maintaining metastasis-free survival (MFS) [...]

Metastatic Prostate Cancer – Bone Metastases Might Be Controled With Xofigo For Two or More Years

Metastatic Prostate Cancer suffers have good news.  Xofigo, also known as Radium-223 (Ra-223), is a treatment for patients with castration-resistant prostate cancer (CRPC) and symptomatic (you can feel them) bone metastases (mets).  Early results of an international, open-label, phase 1/2 study (NCT01934790) showed that re-treating pts with Ra-223 was well tolerated with favorable effects on [...]

By |2018-02-06T11:09:18-05:00February 5th, 2018|Advanced Prostate Cancer, Hormone Therapy|0 Comments